NCT04346108View on ClinicalTrials.gov

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
BIOLOGICAL

Immune Globulin Intravenous (IGIV)

Participants will receive IGIV infusion.

BIOLOGICAL

Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)

Participants will receive IGSC, 20% SC infusion.

Trial Locations (8)

466-8560

Nagoya University Hospital, Nagoya

812-8582

Kyushu University Hospital, Fukuoka

830-0011

Kurume University Hospital, Kurume-shi

501-1194

Gifu University Hospital, Gifu

734-8551

Hiroshima University Hospital, Hiroshima

920-8641

Kanazawa University Hospital, Kanazawa

359-8513

National Defense Medical College Hospital, Tokorozawa-shi

113-8519

Tokyo Medical Dental University Hospital, Bunkyo-ku

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT04346108 - A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) | Biotech Hunter | Biotech Hunter